Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSBR NASDAQ:TARA NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$5.98-1.5%$5.98$5.50▼$9.63$83.06M0.427,739 shs16,197 shsTARAProtara Therapeutics$4.34-5.7%$5.24$2.77▼$7.82$243.91M1.53947,823 shs497,071 shsXFORX4 Pharmaceuticals$3.64-1.1%$4.14$1.35▼$4.83$343.33M0.31447,354 shs446,987 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology-1.69%+1.41%+0.43%+3.83%-3.71%TARAProtara Therapeutics-9.80%-12.71%-15.44%-29.77%+44.20%XFORX4 Pharmaceuticals-6.60%-18.22%-14.22%+18.71%+26.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSBRChampions Oncology$5.98-1.5%$5.98$5.50▼$9.63$83.06M0.427,739 shs16,197 shsTARAProtara Therapeutics$4.34-5.7%$5.24$2.77▼$7.82$243.91M1.53947,823 shs497,071 shsXFORX4 Pharmaceuticals$3.64-1.1%$4.14$1.35▼$4.83$343.33M0.31447,354 shs446,987 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSBRChampions Oncology-1.69%+1.41%+0.43%+3.83%-3.71%TARAProtara Therapeutics-9.80%-12.71%-15.44%-29.77%+44.20%XFORX4 Pharmaceuticals-6.60%-18.22%-14.22%+18.71%+26.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSBRChampions Oncology 1.00SellN/AN/ATARAProtara Therapeutics 2.83Moderate Buy$24.50464.52% UpsideXFORX4 Pharmaceuticals 2.40Hold$8.50133.52% UpsideCurrent Analyst Ratings BreakdownLatest TARA, CSBR, and XFOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026TARAProtara Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$27.00 ➝ $26.005/11/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026TARAProtara Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $27.004/27/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026TARAProtara Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026XFORX4 Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/16/2026CSBRChampions Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D-)3/10/2026TARAProtara Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/9/2026XFORX4 Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSBRChampions Oncology$56.94M1.47$0.44 per share13.52$0.27 per share22.26TARAProtara TherapeuticsN/AN/AN/AN/A$3.80 per shareN/AXFORX4 Pharmaceuticals$35.11M9.78N/AN/A$2.13 per share1.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSBRChampions Oncology$4.70M-$0.16N/AN/AN/A-3.94%-57.31%-7.51%7/16/2026 (Estimated)TARAProtara Therapeutics-$57.44M-$1.34N/AN/AN/AN/A-38.70%-36.02%7/30/2026 (Estimated)XFORX4 Pharmaceuticals-$79.20M-$4.54N/AN/AN/A-1,106.30%-94.90%-48.09%8/6/2026 (Estimated)Latest TARA, CSBR, and XFOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TARAProtara Therapeutics-$0.36-$0.31+$0.05-$0.31N/AN/A5/6/2026Q1 2026XFORX4 Pharmaceuticals-$0.20-$0.16+$0.04-$0.16$3.20 million$2.71 million3/17/2026Q4 2025XFORX4 Pharmaceuticals-$0.36-$0.22+$0.14$1.00$1.68 million$2.57 million3/10/2026Q4 2025TARAProtara Therapeutics-$0.34-$0.37-$0.03-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSBRChampions OncologyN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSBRChampions OncologyN/A0.980.98TARAProtara TherapeuticsN/A15.6915.69XFORX4 Pharmaceuticals0.4510.189.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSBRChampions Oncology41.30%TARAProtara Therapeutics38.13%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipCSBRChampions Oncology46.40%TARAProtara Therapeutics7.60%XFORX4 Pharmaceuticals1.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSBRChampions Oncology14313.89 million7.44 millionOptionableTARAProtara Therapeutics3056.20 million51.93 millionOptionableXFORX4 Pharmaceuticals8094.32 million93.25 millionNo DataTARA, CSBR, and XFOR HeadlinesRecent News About These CompaniesX4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should KnowMay 18 at 1:01 PM | zacks.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 15, 2026 | finance.yahoo.comHere is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy NowMay 14, 2026 | insidermonkey.comGuggenheim Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)May 11, 2026 | theglobeandmail.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by BrokeragesMay 11, 2026 | marketbeat.comQ2 EPS Forecast for X4 Pharmaceuticals Raised by AnalystMay 11, 2026 | marketbeat.comResearch Analysts Issue Forecasts for XFOR FY2029 EarningsMay 8, 2026 | marketbeat.comX4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings ResultsMay 6, 2026 | marketbeat.comX4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2026 | zacks.comX4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI®May 6, 2026 | quiverquant.comQX4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 6, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) to Release Earnings on ThursdayApril 30, 2026 | marketbeat.comX4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European UnionApril 29, 2026 | globenewswire.comOne X4 Pharmaceuticals Insider Raised Their Stake In The Previous YearApril 9, 2026 | finance.yahoo.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2026 | globenewswire.comX4 Pharmaceuticals (XFOR) price target increased by 25.00% to 11.90March 27, 2026 | msn.comX4 Jumps on Q4 FiguresMarch 17, 2026 | baystreet.caX4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue EstimatesMarch 17, 2026 | zacks.comX4 Pharmaceuticals Reports Positive EMA Opinion on Mavorixafor and Updates on 4WARD Phase 3 Trial Enrollment ProgressMarch 17, 2026 | quiverquant.comQX4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 17, 2026 | globenewswire.comGuggenheim initiates coverage of X4 Pharmaceuticals (XFOR) with buy recommendationMarch 10, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTARA, CSBR, and XFOR Company DescriptionsChampions Oncology NASDAQ:CSBR$5.98 -0.09 (-1.48%) Closing price 03:48 PM EasternExtended Trading$5.94 -0.04 (-0.67%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Protara Therapeutics NASDAQ:TARA$4.34 -0.26 (-5.65%) Closing price 04:00 PM EasternExtended Trading$4.34 0.00 (-0.12%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.X4 Pharmaceuticals NASDAQ:XFOR$3.64 -0.04 (-1.09%) Closing price 04:00 PM EasternExtended Trading$3.58 -0.06 (-1.62%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas HIVE Weaponizes Power for an AI Pivot Why Home Depot’s Sell-Off Could Become a Huge Opportunity Brady Corp Wires Up a Massive AI-Powered Breakout AAPL: Forget the iPhone—Services Will Drive the Next Phase of Growth Nebius Group Pulls Back 9% After a Downgrade Despite Strong Earnings A Deep Dive Into NVIDIA’s Latest Portfolio Moves The $132 Billion Infrastructure Pivot You Might Have Missed The Pentagon's AI Pivot Supercharges Defense Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
